• FLASCO
• March 10, 2015
• Drugs

IMBRUVICA® (ibrutinib)

Pharmacyclics, Inc. and Janssen Biotech, Inc., are pleased to announce that, as of January 29, 2015, IMBRUVICA® (ibrutinib) has been granted regular approval by the FDA for use in patients with Waldenström’s Macroglobulinemia (WM). For updated information, please see accompanying Full Prescribing Information